Structural Heart Devices Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (SAVR (Surgical Aortic Valve Replacement), TAVR (Transcatheter Aortic Valve Replacement), Mitral Repair (Annuloplasty), LAAC (Left Atrial Appendage Closure)), By Region and Competition, 2020-2030F

Market Overview

The Global Structural Heart Devices Market, valued at USD 7.20 Billion in 2024, is projected to experience a CAGR of 9.11% to reach USD 12.15 Billion by 2030. Structural heart devices comprise medical implants and systems addressing anatomical defects or disorders of the heart's valves, chambers, or major arteries, typically via minimally invasive procedures. Market growth is fueled by the escalating global prevalence of structural heart diseases, particularly in the aging population. The increasing adoption of minimally invasive interventions, such as Transcatheter Aortic Valve Replacement, offering reduced recovery times and improved patient outcomes, further propels market expansion, alongside ongoing technological advancements.

Illustrating market impact, according to the American Heart Association, over 12% of older Americans faced aortic stenosis in May 2024. Concurrently, the Deutsche Gesellschaft reported 23,752 TAVR procedures in Germany during 2023, reflecting robust clinical uptake. A significant challenge impeding market expansion is the substantial cost associated with these advanced devices, coupled with complex and stringent regulatory approval processes across regions.

Key Market Drivers

The rising prevalence of structural heart diseases represents a fundamental driver for the global structural heart devices market, creating a substantial and expanding patient demographic requiring advanced therapeutic interventions. Conditions such as valvular heart disease, cardiomyopathy, and congenital heart defects, which often necessitate mechanical correction or replacement, are increasingly being diagnosed due to improved awareness and diagnostic capabilities. This growing disease burden directly translates into a higher demand for innovative devices like transcatheter heart valves and annuloplasty rings. For instance, according to "The Global Burden of Valvular Heart Disease: From Clinical Epidemiology to Management", in March 2023, more than 4% of people over 75 years old were found to have a clinically relevant tricuspid regurgitation, highlighting the significant need for effective treatment solutions for various structural heart conditions beyond previously highlighted disorders. The expansion of the treatable patient population directly fuels investment in device development and clinical adoption.

Concurrently, the aging global population significantly influences market expansion. As individuals live longer, they are more susceptible to age-related degenerative heart conditions that impact structural integrity, amplifying the incidence of various structural heart diseases. This demographic shift not only increases the absolute number of potential patients but also often presents with comorbidities that make traditional open-heart surgery a higher risk, thereby favoring minimally invasive device-based treatments. According to the World Health Organization, in October 2025, the proportion of the world's population over 60 years is projected to nearly double from 12% in 2015 to 22% by 2050. This demographic trend ensures a sustained and growing need for structural heart interventions. The overall market for these devices benefits significantly from technological advancements enabling safer and more effective procedures. For example, according to the American College of Cardiology's Annual Scientific Session, in March 2023, transcatheter-based mitral valve repair was successful in nearly 90% of patients, effectively reducing valve leakage from severe to moderate or less, demonstrating the strong clinical utility and patient outcomes driving market growth.

Download Free Sample Report

Key Market Challenges

The substantial cost associated with advanced structural heart devices presents a significant impediment to the growth of the Global Structural Heart Devices Market. These high expenses directly impact healthcare budgets and reimbursement policies, particularly in health systems with constrained financial resources. This economic barrier can restrict the widespread adoption of innovative therapies, limiting access for a broader patient population across different economic regions.

The elevated cost of these devices also contributes to slower market penetration as healthcare providers and payers face pressure to manage expenditures. According to the American Heart Association, in a May 2023 analysis of the PARTNER 3 trial, procedural costs for Transcatheter Aortic Valve Replacement were nearly $19,000 higher compared to surgical aortic valve replacement. Such high initial costs for devices can strain hospital budgets, influencing procurement decisions and potentially leading to delays in making these advanced treatments widely available. This directly hampers overall market expansion by limiting the volume of procedures performed and delaying wider patient access to these crucial interventions.

Key Market Trends

Advancements in Interventional Imaging and AI-Guided Navigation
This trend underscores the evolving sophistication of imaging modalities and the integration of artificial intelligence in guiding structural heart interventions. These technological enhancements improve procedural precision and safety, ultimately contributing to favorable patient outcomes. AI-driven algorithms assist in real-time visualization, optimal device placement, and comprehensive pre-procedural planning, which can refine procedural pathways. For instance, according to the American College of Cardiology's Annual Scientific Session, in March 2025, patients whose evaluation was non-invasively guided by a novel, AI-powered technique underwent approximately 10% fewer procedures with comparable outcomes to those guided by ultrasound-based imaging. This demonstrates the capacity of advanced imaging and AI to enhance efficiency and effectiveness in complex cardiac procedures.

Decentralization of Procedures to Ambulatory Surgical Centers
The growing shift of eligible structural heart procedures to ambulatory surgical centers (ASCs) represents a significant transformation in healthcare delivery. This movement aims to reduce healthcare costs and enhance patient convenience by performing less complex interventions in an outpatient setting. Such decentralization expands patient access to advanced therapies, particularly for lower-risk individuals. According to the Society for Cardiovascular Angiography & Interventions, in May 2025, ASC volume is anticipated to increase by 21% between 2024 and 2034, highlighting a substantial projected migration of cardiac procedures to these outpatient facilities. This trend is expected to continue as clinical data further supports the safety and efficacy of performing certain cardiac interventions outside traditional hospital environments.

Segmental Insights

The key segmental insight within the Global Structural Heart Devices Market highlights Transcatheter Aortic Valve Replacement (TAVR) as the fastest-growing segment. This rapid expansion is primarily driven by its minimally invasive nature, which offers reduced recovery times and hospital stays compared to traditional open-heart surgery. Furthermore, supportive clinical data and subsequent regulatory approvals, such as those granted by the U. S. Food and Drug Administration (FDA), have broadened the indications for TAVR to include lower-risk patient populations, substantially increasing its market penetration and adoption. These factors collectively contribute to TAVR's significant growth and increasing preference among both patients and healthcare providers.

Regional Insights

North America maintains its leading position in the global structural heart devices market due to a convergence of distinct advantages. The region experiences a significant prevalence of structural heart diseases, driving consistent demand for advanced treatment options. Its sophisticated healthcare infrastructure, comprising well-equipped hospitals and specialized cardiac centers, enables the swift adoption and integration of innovative device technologies. Moreover, the presence of major medical device manufacturers fosters continuous research and development, ensuring access to a pipeline of cutting-edge structural heart solutions. A supportive regulatory environment, characterized by frequent product approvals from agencies like the Food and Drug Administration (FDA), further accelerates market expansion.

Recent Developments

• In November 2024, Medtronic initiated a multicenter study, known as ALERT, in collaboration with Tempus, a health technology company. This randomized study aims to address health disparities and undertreatment of severe aortic stenosis and moderate to severe mitral regurgitation. Utilizing artificial intelligence through the Tempus Next platform, the research seeks to identify patients who meet guideline-indicated therapy criteria but currently lack a treatment plan, particularly for minimally invasive therapies like transcatheter aortic valve replacement (TAVR). This collaboration represents a significant research effort within the global structural heart devices market to improve equitable access to advanced care.

• In August 2024, Boston Scientific Corporation obtained CE Mark approval for its ACURATE Prime™ Aortic Valve System. This newest transcatheter aortic valve replacement (TAVR) technology within the company's structural heart portfolio builds upon the ACURATE neo2™ platform. The ACURATE Prime system includes an expanded valve size, allowing treatment for patients with a wider range of anatomical characteristics. This regulatory clearance permits its availability for patients with aortic annulus diameters between 20.5 and 29 mm, further strengthening Boston Scientific's offerings in the global structural heart devices market by enhancing design features and clinical performance.

• In July 2024, Edwards Lifesciences announced strategic investments to acquire JenaValve Technology and exercised an option to acquire Endotronix. The acquisition of JenaValve, a pioneer in transcatheter aortic regurgitation treatment, is expected to bring the JenaValve Trilogy System closer to FDA approval in late 2025, representing a potential first approved therapy for severe symptomatic aortic regurgitation. Concurrently, the Endotronix acquisition expands Edwards' structural heart portfolio into heart failure management with the Cordella System, an implantable pulmonary artery pressure sensor, addressing significant unmet patient needs within the global structural heart devices market.

• In April 2024, Abbott received U.S. Food and Drug Administration (FDA) approval for its TriClip™ transcatheter edge-to-edge repair (TEER) system. This device is specifically designed for treating tricuspid regurgitation, a condition characterized by a leaky tricuspid heart valve. Clinical data from the TRILUMINATE Pivotal trial demonstrated that patients treated with TriClip experienced significant improvements in symptom severity and quality of life, with benefits maintained for one year. This approval marked a crucial advancement in the global structural heart devices market by offering a minimally invasive option for patients unsuitable for open-heart surgery, expanding treatment accessibility for this often-undertreated condition.

Key Market Players

• Abbott Laboratories, Inc.
• Edwards Lifesciences Corporation
• Medtronic Plc
• Boston Scientific Corporation
• Lepu Medical Technology Holding Company
• TTK Healthcare Limited
• Biomerics, LLC
• Braile Biomedic
• Artivion, Inc.
• JenaValve Technology Inc

Report Scope:

In this report, the Global Structural Heart Devices Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Structural Heart Devices Market, By Type:

o   SAVR (Surgical Aortic Valve Replacement)

o   TAVR (Transcatheter Aortic Valve Replacement)

o   Mitral Repair (Annuloplasty)

o   LAAC (Left Atrial Appendage Closure)

• Structural Heart Devices Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Structural Heart Devices Market.

Available Customizations:

Global Structural Heart Devices Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Structural Heart Devices Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]